In-depth biotech analysis articles

In Depth 16 Nov 2023

uniQure: is the gene therapy pioneer en route to becoming a biotech rebuff?

Once thought to be a frontrunner in gene therapy, uniQure’s fame may no longer be coveted, as the biotech looks to reorganize by slashing its workforce, in an attempt to stay afloat. But how did things go awry for the company that was once in its prime in the DNA game? The Danish company, which […]

November 16, 2023 - 7 minutesmins - By Roohi Mariam Peter

In Depth 16 Nov 2023

Meet the ‘biotech mafia’: how specialized biotech VC firms are dominating industry funding once again

Between 2020 and 2022 – largely due to the biotech innovations that came about by the COVID-19 pandemic – there was an influx of generalist investors in the biotech industry, betting big on new technologies like mRNA vaccines. But, now, these investors appear to have backed off, leaving room for specialized biotech venture capital (VC) […]

November 16, 2023 - 6 minutesmins - By Willow Shah-Neville

In Depth 15 Nov 2023

Beyond oil and gas: Biotech’s significant place in the Qatar Investment Authority’s strategy

Since 2020, the Qatar Investment Authority (QIA) has been taking part in important biotech fundings reaching its peak in 2021 and remaining strong in 2023. They recently led a $250 million round in the company BridgeBio specialized in transformative medicine for patients suffering from cancer or genetic diseases. This investment is not an isolated case […]

November 15, 2023 - 8 minutesmins - By Jules Adam

In Depth 9 Nov 2023

Blood tests for Alzheimer’s: a hit or a miss?

Doctor’s typically diagnose Alzheimer’s with the help of brain imaging and cognitive tests, along with taking a patient’s medical history into account. But lately, blood tests are gaining recognition for its ability to rule out other potential causes of memory loss, and to diagnose Alzheimer’s more quickly. With American healthcare company Labcorp launching its trio […]

November 9, 2023 - 10 minutesmins - By Roohi Mariam Peter

In Depth 8 Nov 2023

Promising cure for COPD: is a breakthrough treatment within reach?

Did you know that chronic obstructive pulmonary diseases (COPD) is actually the third leading cause of death worldwide? According to the World Health Organization (WHO), the lung disease – which restricts airflow and causes breathing problems – led to 3.23 million deaths in 2019 alone. This highlights the critical need for finding a treatment that […]

November 8, 2023 - 7 minutesmins - By Willow Shah-Neville

In Depth 6 Nov 2023

The biggest private biotech investments in October 2023

The companies Aiolos Bio, MapLight Therapeutics and Agomab Therapeutics bagged the biggest biotech investments in October 2023. Around the world, biomaterials, central nervous system and musculoskeletal disorder players attracted the most investor interest. October 2023 saw a lot of fundraising taking place both in and out of healthcare in the U.S. and Europe. However, the […]

November 6, 2023 - 3 minutesmins - By Willow Shah-Neville

In Depth 2 Nov 2023

How French pharma giant Sanofi is betting big on AI

The benefits of artificial intelligence (AI) in shaping clinical research and trials have given rise to many new AI-driven biotech startups. According to a recent report, the number of AI companies involved in drug discovery and development increased from 62 in 2011 to 400 in 2022. This AI-driven transformation is catching the attention of big pharma […]

November 2, 2023 - 8 minutesmins - By Willow Shah-Neville

In Depth 30 Oct 2023

The ongoing search for an HIV cure: can CRISPR crack the code?

HIV continues to represent a global health burden, with the World Health Organization (WHO) estimating that, in 2022, there were 39 million people living with the virus. But there is still no effective cure for it. The only option patients have is antiretroviral therapy, which, although it represents a major milestone in HIV treatment and […]

October 30, 2023 - 7 minutesmins - By Willow Shah-Neville

In Depth 27 Oct 2023

Big pharma monopolies: major antitrust cases over the past decade

Antitrust laws are put in place to prevent unlawful activities like price fixing, as well as monopolies from forming, typically tied to big pharma. If these powerful companies were to swallow smaller biotechs in an attempt to fix prices, it would stifle competition, result in limited options for consumers, thereby leading to a rise in […]

October 27, 2023 - 11 minutesmins - By Roohi Mariam Peter

In Depth 26 Oct 2023

Behind closed doors: The unseen controversies and scandals in Alzheimer’s drug trials

Alzheimer’s disease is the most common form of dementia – which currently affects more than 55 million people globally – making up 60% to 70% of cases. It is a complex disease, encompassing multiple interrelated and progressive destructive processes in the brain, resulting in neuron damage that extends to parts of the brain that enable […]

October 26, 2023 - 11 minutesmins - By Willow Shah-Neville

In Depth 20 Oct 2023

Is Africa ready to become the next big biopharma and vaccine manufacturing destination?

Localizing pharma manufacturing worldwide is an extremely important step, and it holds particular significance for Africa. The continent is more vulnerable to disease burdens and lags behind other continents when it comes to vaccine and general healthcare access. Localized manufacturing could help people in Africa gain easier and more affordable access to vaccines and other […]

October 20, 2023 - 10 minutesmins - By Willow Shah-Neville

In Depth 19 Oct 2023

Biotech’s battle against NASH: The ongoing pursuit of an effective treatment

NASH is one of the most common reasons for a patients receiving a liver transplant. The condition is a severe form of non-alcoholic fatty liver disease (NAFLD), whereby fat builds up on the liver, potentially leading to liver damage or cirrhosis. And, yet, despite the severity of the disease, there are still no approved NASH […]

October 19, 2023 - 8 minutesmins - By Willow Shah-Neville

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us